



ASX release

25 January 2017

Central Blood Pressure Associated with Cognitive Decline

AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system for advanced hypertension management, today announced the publication of a new journal article: “Association between central blood pressure, arterial stiffness, and mild cognitive impairment”¹ in the journal *Clinical Hypertension*. The purpose of this study was to determine the relationship between central blood pressure (CBP) and mild cognitive impairment (MCI) in adults over the age of 50.

In the study, central blood pressure and brachial (arm) blood pressure were measured in 50 patients. AtCor Medical’s SphygmoCor XCEL system was used to assess central aortic blood pressure. There was no significant association found between brachial blood pressure and cognition. However, a significant relationship was observed between central blood pressures, specifically augmentation index (AI) and pulse pressure amplification (PPA), and mild cognitive decline.

The authors stated: “Although blood pressure is typically measured peripherally over the brachial artery, central blood pressure measurements, including aortic blood pressure, have shown stronger associations with end-organ damage and may be of greater clinical use.” The authors concluded; “CBP indices like AI and PPA, which are markers of vascular stiffness, are associated with poor executive function and language cognitive domain deficits.”

AtCor Medical chief executive officer, Duncan Ross, said: “A number of studies have established a relationship between central aortic blood pressures, arterial stiffness and cognitive decline, and we are pleased to see continued research in this important new clinical application. As we continue to introduce SphygmoCor to the clinical market, it is important to be able to share this new data with doctors to further demonstrate the broader impact SphygmoCor can have on patient management.”

About AtCor Medical

AtCor Medical develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company’s SphygmoCor system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions, effects which cannot be detected with standard brachial blood pressure measurements. SphygmoCor is essential for hypertension management.

¹ Suleman. R., et. al. **Association between central blood pressure , arterial stiffness, and mild cognitive impairment**, *Clinical Hypertension* (2017) 23:2
<https://clinicalhypertension.biomedcentral.com/articles/10.1186/s40885-016-0058-5>

SphygmoCor® is a registered trademark of AtCor Medical Pty Ltd and its related parties

For personal use only

More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 8815 8811

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au